Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study found that young males with stage III or higher androgenetic alopecia had higher insulin resistance and cardiovascular-related features, suggesting the need for metabolic assessment in this population.

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.

This study found that men with a paternal history of hair loss were significantly more likely to experience hair loss themselves.

In this study, female androgenic alopecia (grade II or III on Ludwig's scale) was found to be common among Finnish women aged 63, and several markers of insulin resistance, along with paternal history of alopecia, were associated with an increased risk.

This study found that combining microneedling with PRP and topical minoxidil (5%) significantly improved hair growth in men with androgenetic alopecia compared to using minoxidil alone.

This study found that androgenic alopecia is present in 22% of women with polycystic ovary syndrome and is associated with acne and hirsutism, but not with increased biochemical hyperandrogenemia or metabolic dysfunction beyond PCOS.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This article reviews the classification, diagnosis, and management of hair disorders, emphasizing the role of trichoscopy and early diagnosis for effective treatment but reports no new clinical findings.

This study found that DKK1 and WNT10b are paracrine factors that modulate hair follicle stem cell differentiation inhibition, contributing to androgenetic alopecia by affecting Wnt signaling in androgen-sensitive dermal papilla cells after dihydrotestosterone stimulation.

This article reviews mechanisms by which herbal ingredients may stimulate or inhibit hair growth, and it reports no new clinical findings while suggesting potential for developing hair loss treatments.

This study suggests men with early androgenetic alopecia might have hormonal profiles similar to women with polycystic ovarian syndrome, potentially indicating risk for related health complications.

This review found that low-level laser therapy appears promising in improving hair regrowth and patient satisfaction in androgenetic alopecia, though results should be interpreted cautiously.

This review explores genetic and lifestyle factors influencing hair diversity and reports no new findings, calling attention to the potential for future discoveries in genetic and epigenetic research.

In this study, decreased expression of BMP2 and ephrin A3 and increased NT-4 gene expression were observed in dermal papilla cells from androgenic alopecia-affected skin, suggesting potential roles in hair growth regulation.

This study showed that Thujae occidentalis semen extract inhibited 5alpha-reductase type 2 in laboratory tests and reduced androgen-related hair loss in animal models, suggesting potential use for male pattern baldness.

This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.

In this study, subdermal platelet-rich plasma injections significantly increased hair count and shaft caliber in individuals with androgenetic alopecia, with monthly treatments potentially offering greater benefits.

This study suggests that down-regulation of vasculature-related genes in dermal papilla cells from balding scalps might contribute to the development of androgenetic alopecia.

This review discusses the genetic research developments in androgenetic alopecia, reporting no new clinical results, and highlights the potential for discovering novel therapeutic targets.

This study found that trichodynia is common among patients with telogen effluvium and androgenetic alopecia, and it often coexists with psychological issues like depression and anxiety.

In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.

Vitiligo is not linked to coeliac disease, but a small number of alopecia areata patients may have it, suggesting they should be tested for coeliac disease.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

This study found that plasmacytoid dendritic cells are central to the pathogenesis of alopecia areata, suggesting they may help differentiate it from trichotillomania and androgenetic alopecia.

This study found that low-level laser therapy may improve hair growth in patients with androgenetic alopecia, either as a standalone treatment or combined with minoxidil or finasteride, without reported adverse reactions.

This study found that women with early-onset androgenetic alopecia had higher aldosterone levels and blood pressure, suggesting a possible link to the increased prevalence of hypertension in this group.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.